Skip to main content
. Author manuscript; available in PMC: 2014 Mar 21.
Published in final edited form as: J Neurochem. 2012 Aug 23;123(2):288–297. doi: 10.1111/j.1471-4159.2012.07875.x

Figure 4. PMA increased DAT immunoreactivity within the synaptosomal vesicle fractions.

Figure 4

Striatal synaptosomes were treated with 10 μM phorbol 12-myristate 13-acetate (PMA) for 30 min at 37 °C (n = 6 per group). Following treatment, synaptosomal membrane and vesicle fractions were isolated and DAT immunoreactivity was measured by densitometry. (A) DAT immunoreactivity was increased within PMA-treated vesicles as compared to saline-treated vesicles. (B) No difference in DAT immunoreactivity was observed between PMA- and saline-treated synaptosomal membranes. ** Treatment across fractions different than saline-treated fractions (p ≤ 0.01). ‘DAT P’ indicates DAT peptide control lane.